Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 20, 2022

Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity in US Facility

Catalent has announced a $175 million project to expand its manufacturing facility for large scale oral dose forms at its Winchester, Ky, site.

Catalent announced on May 19, 2022 that it has begun a $175 million project to expand its manufacturing facility in Winchester, Ky. According to a company press release, the facility, which specializes in large-scale oral dose forms, will have two new buildings and a total of 107,000 ft² added to its manufacturing footprint.

The expansion is slated to broaden the site’s highly potent material handling capabilities and containment vault, provide additional laboratory space, and add further capacity for existing turnkey operations, such as dual fill encapsulation and pan coating. These expansions follow a 2015 doubling of the site’s footprint to 190,000 ft² and a $40 million investment in 2019 that installed new equipment for stick pack dosage manufacturing, integrated packaging lines, and expanded roller compaction and fluid bed capacity.

“We are witnessing a broad increase in demand for manufacturing, and the nature of the development pipeline being strong in both oncology treatments and complex molecules, necessitates the expansion of specific capabilities in areas such as highly potent materials handling,” said Aris Gennadios, president of softgel and oral technologies, Catalent, in the press release. “Our Winchester site has a rich history in the successful commercialization of new products, and this expansion is the latest in a series of strategic investments, totaling hundreds of millions of dollars, to ensure that the current and future needs of our customers can be met.”

Source: Catalent


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.